There is a risk that using autologous cells from a PD patient who suffers from genetic defects may prevent therapeutic efficacy due to mutant SNCA, leucine-rich repeat serine/threonine kinase 2, Parkin, or DJ-1 genes. Here, PRKN is linked to Parkinson disease.